Brean Murray initiates coverage on MedAssets (Nasdaq: MDAS) with a Buy rating. PT $25.

Brean analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE